CDC Panel Votes to Expand RSV Vaccine Use in Older Adults.

RESPIRATORY syncytial virus infection vaccines; OLDER people; MEDICAL protocols; CENTERS for Disease Control & Prevention (U.S.); VACCINE development; INTERNATIONAL travel; AT-risk people; CHIKUNGUNYA virus

A CDC panel has voted to expand the use of vaccines for respiratory syncytial virus (RSV) in older adults, specifically recommending a single dose for high-risk individuals aged 50 to 59. This decision is expected to benefit RSV vaccine manufacturers such as GSK Plc, Pfizer Inc., and Moderna Inc., whose sales declined last year. The panel also recommended a vaccine for chikungunya virus for international travelers visiting countries with outbreaks, as the virus can cause fevers and joint pain and has been reported in various regions worldwide. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)